🇪🇺 H5G1.1 in European Union

EMA authorised H5G1.1 on 20 June 2007

Marketing authorisation

EMA — authorised 20 June 2007

  • Status: approved

H5G1.1 in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Neuroscience approved in European Union

Frequently asked questions

Is H5G1.1 approved in European Union?

Yes. EMA authorised it on 20 June 2007.

Who is the marketing authorisation holder for H5G1.1 in European Union?

AstraZeneca is the originator. The local marketing authorisation holder may differ — check the official source linked above.